MedPath

Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Phase 3
Completed
Conditions
Spasticity
Interventions
Drug: Placebo0921
Registration Number
NCT01457352
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Brief Summary

The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
392
Inclusion Criteria
  • Men and women age 18 years and older
  • Able and willing to comply with the protocol, including availability for a scheduled clinic visits
  • Willingness and giving of written informed consent
Exclusion Criteria
  • In relapse or history of unstable course over the prior 30 days prior to the Screening Visit
  • Concomitant neurologic conditions causing spasticity
  • Has received an investigational drug or device within 30 days that would interfere with the study goals prior to the Screening Visit
  • Unable to comply with study procedures in the opinion of the investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo0921Placebo0921-
SPARC0921SPARC0921-
Primary Outcome Measures
NameTimeMethod
Treatment Failure RateWeek 22

Percentage of subjects who had treatment failure Clinical Global Impression of Change of ≥ 5 and at least one movement with ≥ 1 unit increase in modified Ashworth score from baseline.

The modified Ashworth scale is a 6-point scale as follows: Minimum score of 0 (better outcome) = no increase in tone Maximum score of 4 (worst outcome) = affected part(s) rigid inflexion or extension.

The clinician (other than the one performing the Modified Ashworth Scale assessment) rated his/her overall (global) impression of change in spasticity using the 7-point scale shown below: Minimum score of 1 (better outcome) = very much improved Maximum score of 7 (very much worse) = very much worse

Secondary Outcome Measures
NameTimeMethod
Severity of Spasticity Assessed by Subject Global Impression Severity ScaleWeek 22

The subject was asked "Overall, how would you rate the severity of your spasticity over the past 24 hours?" The 7-point scale for Subject's global impression of severity assessment is as follows: minimum score of 1 = normal, no spasticity maximum score of 7 (worst outcome)= worst spasticity imaginable

Trial Locations

Locations (73)

SPARC site 6

🇺🇸

Gilbert, Arizona, United States

SPARC Site 40

🇺🇸

Phoenix, Arizona, United States

SPARC Site 36

🇺🇸

Costa Mesa, California, United States

SPARC Site 20

🇺🇸

Newport Beach, California, United States

SPARC Site 38

🇺🇸

Basalt, Colorado, United States

SPARC Site 21

🇺🇸

Denver, Colorado, United States

SPARC Site 9

🇺🇸

Derby, Connecticut, United States

SPARC Site 57

🇺🇸

Hartford, Connecticut, United States

SPARC Site 10

🇺🇸

New London, Connecticut, United States

SPARC Site 60

🇺🇸

Washington, District of Columbia, United States

Scroll for more (63 remaining)
SPARC site 6
🇺🇸Gilbert, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.